[Translation] A single-center, open-label, randomized clinical study on the pharmacokinetics and interactions of single and multiple doses of ceftriaxone sodium and tazobactam sodium for injection

健康受试者进行注射用头孢曲松钠他唑巴坦钠的药代动力学试验，测定主要成分头孢曲松钠和他唑巴坦钠的经时血药浓度，计算主要药代动力学参数，了解注射用头孢曲松钠他唑巴坦钠在人体吸收、分布、消除、代谢规律，为制定注射用头孢曲松钠他唑巴坦钠II期临床试验方案提供试验依据。

[Translation]

A pharmacokinetic study of ceftriaxone sodium and tazobactam sodium for injection was conducted on healthy subjects to determine the time-dependent blood concentrations of the main components, ceftriaxone sodium and tazobactam sodium, and calculate the main pharmacokinetic parameters to understand the absorption, distribution, elimination, and metabolism of ceftriaxone sodium and tazobactam sodium for injection in the human body, so as to provide an experimental basis for the formulation of the Phase II clinical trial plan for ceftriaxone sodium and tazobactam sodium for injection.

Start Date22 Jul 2010

Sponsor / Collaborator

China Pharma Holdings, Inc.

CTR20150076

/ Not yet recruitingPhase 3

注射用头孢曲松钠他唑巴坦钠（6:1）治疗中、重度下呼吸道和泌尿系统急性细菌感染有效性和安全性的Ⅲ期临床试验

[Translation] Phase III clinical trial of the efficacy and safety of ceftriaxone sodium and tazobactam sodium for injection (6:1) in the treatment of moderate to severe acute bacterial infections of the lower respiratory tract and urinary system

以注射用头孢曲松钠他唑巴坦钠（3:1）为对照，进一步评价注射用头孢曲松钠他唑巴坦钠（6:1）治疗中、重度下呼吸道和泌尿系统急性细菌感染的有效性和安全性。

[Translation]

Using ceftriaxone sodium and tazobactam sodium for injection (3:1) as a control, the efficacy and safety of ceftriaxone sodium and tazobactam sodium for injection (6:1) in the treatment of moderate to severe acute bacterial infections of the lower respiratory tract and urinary system were further evaluated.

Start Date-

Sponsor / Collaborator

Xiangbei Welman Pharmaceutical Co., Ltd.

CTR20130987

/ RecruitingPhase 2

注射用头孢曲松钠他唑巴坦钠（6:1）治疗中、重度下呼吸道和泌尿系统急性细菌感染的Ⅱ期临床试验

[Translation] Phase II clinical trial of ceftriaxone sodium and tazobactam sodium for injection (6:1) in the treatment of moderate to severe acute bacterial infections of the lower respiratory tract and urinary system

以注射用头孢曲松钠他唑巴坦钠（3:1）为对照，评价注射用头孢曲松钠他唑巴坦钠（6:1）治疗中、重度下呼吸道和泌尿系统急性细菌感染的有效性和安全性。

[Translation]

To evaluate the efficacy and safety of ceftriaxone sodium and tazobactam sodium for injection (6:1) in the treatment of moderate to severe acute bacterial infections of the lower respiratory tract and urinary system, using ceftriaxone sodium and tazobactam sodium for injection (3:1) as a control.

Start Date-

Sponsor / Collaborator-

100 Clinical Results associated with Ceftriaxone Sodium/Tazobactam Sodium

100 Translational Medicine associated with Ceftriaxone Sodium/Tazobactam Sodium

100 Patents (Medical) associated with Ceftriaxone Sodium/Tazobactam Sodium

100 Deals associated with Ceftriaxone Sodium/Tazobactam Sodium

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bacterial Infections	China	Haikou Qili Pharmaceutical Co., Ltd.	09 Apr 2009

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bacterial lower respiratory infection	Phase 3	China	Xiangbei Welman Pharmaceutical Co., Ltd.	16 Apr 2015
Genitourinary tract infection	Phase 3	China	Xiangbei Welman Pharmaceutical Co., Ltd.	16 Apr 2015
Acute Bronchitis	Phase 2	China	Xiangbei Welman Pharmaceutical Co., Ltd.	17 May 2011
Acute pyelonephritis	Phase 2	China	Xiangbei Welman Pharmaceutical Co., Ltd.	17 May 2011
Bronchiectasis	Phase 2	China	Xiangbei Welman Pharmaceutical Co., Ltd.	17 May 2011
Community Acquired Pneumonia	Phase 2	China	Xiangbei Welman Pharmaceutical Co., Ltd.	17 May 2011
Complicated urinary tract infection	Phase 2	China	Xiangbei Welman Pharmaceutical Co., Ltd.	17 May 2011
Hospital-acquired pneumonia	Phase 2	China	Xiangbei Welman Pharmaceutical Co., Ltd.	17 May 2011
Pulmonary Disease, Chronic Obstructive	Phase 2	China	Xiangbei Welman Pharmaceutical Co., Ltd.	17 May 2011
Lower Respiratory Tract Infections	Phase 1	China	China Pharma Holdings, Inc.	22 Jul 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis